Romyelocel-L - Cellerant Therapeutics
Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant TherapeuticsLatest Information Update: 28 May 2024
At a glance
- Originator Cellerant Therapeutics
- Class Cell therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia; Transplant rejection
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Transplant-rejection(Prevention) in USA (IV, Infusion)
- 27 Sep 2022 No development reported - Phase-III for Neutropenia in USA (IV)
- 21 Apr 2020 Phase-III clinical trials in Neutropenia in USA (IV) (Cellerant Therapeutics pipeline, April 2020)